Amylx Pharmaceuticals Inc vs Vanguard Total International Bond Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.66 (market cap $2.64B), while Vanguard Total International Bond Index Fund ETF trades at $47.89. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | BNDX | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | — |
52-Week High | $24.19 | $49.91 |
52-Week Low | $7.82 | $47.57 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BNDX trades at $47.91, up 0.25% with neutral technical signals. The ETF shows mixed institutional activity with Apella Capital reducing holdings by 3.0% while Archer Investment increased by 48.2% in Q2 2026. Recent dividend payments of $0.11-$0.12 provide income appeal, though key valuation ratios remain unavailable for analysis.
Outlook remains balanced amid bond market volatility. Rising Treasury yields and inflation concerns create headwinds, while institutional interest and steady dividends offer support. The ETF's international bond exposure provides diversification benefits but remains sensitive to global interest rate movements and geopolitical tensions.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →